Efficacy and Safety of Abbreviated Eptifibatide Treatment in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

In patients with ST-segment elevation myocardial infarction (STEMI), antithrombotic therapy with aspirin, a P2Y12 inhibitor, and heparin is essential to reduce coronary thrombus burden, and to facilitate primary percutaneous coronary intervention (PCI).1,2 In case of periinterventional thrombotic complications, additional use of a glycoprotein IIb/IIIa inhibitor (GPI) is a reasonable bailout treatment.1,2 Eptifibatide is a potent GPI3 that rapidly inhibits platelet aggregation when administered as bolus followed by infusion for 18-24 hours,4 which reduced ischemic endpoints and death in patients undergoing PCI in clinical trials performed in the 1990 ’s.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research